Fund for R&D in Neglected Diseases (FRIND)
Championed by Novartis, the Fund for Research in Neglected Disease (FRIND) would apply the portfolio management techniques used by private pharmaceutical firms for their mainstream drug pipelines for research in neglected disease. The proponents of FRIND argue that many individual research projects, some of which may duplicate efforts, currently compete for an inadequate pool of donor funding. FRIND proposes that all available funding be pooled and then allocated by a board that represents developing countries, major funders, OECD countries and other international health stakeholders. Portfolio management teams functioning underneath this board would guide the R&D for a specific disease. As projects meet milestone targets, additional payments would be made for incremental successes. FRIND proposes data sharing between projects in order speed innovation and stopping or redirecting poorly performing projects as early as possible.
Paul Herrling, Novartis
Dalberg Global Development Advisors. “Feasibility Study for a Fund for R&D for Neglected Diseases.” Commissioned by International Federation of Pharmaceutical Manufacturers & Associations. 28 January 2008.
Herrling, Paul L. “Making drugs accessible to poor populations: a funding model.” Global Forum Update on Research for Health Volume 5: Fostering Innovation for Global Health (2008): 152 – 155. Available here.
International Federation of Pharmaceutical Manufacturers & Associations and Dalberg Global Development Advisors. “Briefing note – Ensuring sustainable funding for R&D into neglected diseases for the developing world.” October 2007.
|Dalberg IFPMA briefing note 07.pdf||68.33 KB|